OTSSP167 (hydrochloride)
OTSSP167 (OTS167) hydrochloride is a highly potent and ATP-competitive MELK inhibitor with IC50 value of 0.41 nM.
Product Specifications
CAS Number
[1431698-10-0]
Product Name Alternative
OTS167 (hydrochloride)
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
MELK
Type
Reference compound
Related Pathways
PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/OTSSP167-hydrochloride.html
Purity
99.78
Solubility
DMSO : 33.33 mg/mL (ultrasonic) |H2O : 7.14 mg/mL (ultrasonic)
Smiles
ClC1=CC(C2=CC=C(N=CC(C(C)=O)=C3N[C@H]4CC[C@H](CN(C)C)CC4)C3=N2)=CC(Cl)=C1O.[H]Cl
Molecular Formula
C25H29Cl3N4O2
Molecular Weight
523.88
Precautions
H302, H315, H319
References & Citations
[1]Chung S, Suzuki H, Miyamoto T, et al. Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget. 2012 Dec 21.|[2]Ji W, et al. OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases. PLoS One. 2016 Apr 15;11 (4) :e0153518.|[3]Cho YS, et al. The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor. Biochem Biophys Res Commun. 2014 Apr 25;447 (1) :7-11.|[4]Jurmeister S, et al. Identification of potential therapeutic targets in prostate cancer through a cross-species approach. EMBO Mol Med. 2018 Feb 5. pii: e8274.|[5]Meel MH, et al. MELK inhibition in Diffuse Intrinsic Pontine Glioma. Clin Cancer Res. 2018 Jul 30. pii: clincanres.0924.2018.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Citation 01
Clin Cancer Res. 2018 Nov 15;24 (22) :5645-5657. |Elife. 2017 Mar 24;6:e24179.|Elife. 2018 Feb 8;7:e32838. |EMBO Mol Med. 2018 Mar;10 (3) . pii: e8274.|Free Radic Biol Med. 2021 Aug 20:172:312-329.|Gynecol Oncol. 2017 Apr;145 (1) :159-166.|Harvard Medical School LINCS LIBRARY|Int J Mol Sci. 2025 Mar 3;26 (5) :2245.|Nat Cancer. 2024 Aug;5 (8) :1250-1266.|Neuro Oncol. 2020 Jan 11;22 (1) :58-69. |University of Washington. 2025.|Adv Ther (Weinh) . 2025 Oct 24.|Biochem Biophys Res Commun. 2014 Apr 25;447 (1) :7-11. |Blood Cancer J. 2019 Nov 18;9 (12) :87.|Eur J Pharmacol. 2025 Oct 5:1004:178017.|Int J Oncol. 2022 Jul;61 (1) :89.|Mol Cancer. 2014 May 4;13:100.|Oncotarget. 2016 Feb 2;7 (5) :6266-80. |Oncotarget. 2017 Dec 20;9 (2) :2591-2602. |Patent. US20160291017A1.|PLoS One. 2017 Feb 24;12 (2) :e0172832. |Sci Rep. 2017 Feb 14;7:42502.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items